The drug, amitriptyline, is a tricyclic antidepressants used in the treatment of various health conditions such as chronic neuropathic pain, depression, and others. The drug is also used off-label in treatment of migraine. Amitriptyline affects certain chemical messengers (neurotransmitters) that communicate between brain cells and help regulate mood. The drug is also available in combinations such as Anxipan (amitriptyline and pantoprazole) and Limbitrol Tablet (amitriptyline and chlordiazepoxide).
The global amitriptyline market is estimated to be valued at US$ 527.4 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
Figure 1. Global Amitriptyline Market Share (%), by Indication, 2020
Global Amitriptyline Market: Driver
Rising concerns about neuropathic pain, migraine, and related disorders are expected to drive demand for amitriptyline and favor growth of the global amitriptyline market. According to clinical evaluation study published in National Center for Biotechnology Information (NCBI) 2010, the estimated community prevalence of neuropathic pain from the clinical examination (gold standard) was 9.8%. The condition is more prevalent among the elderly population.
Moreover, amitriptyline is an effective, off-label, and inexpensive agent that is useful for prevention of migraine, and tension-type headache. According to Migraine Research Foundation, migraine is the third most common disease in the world, and has affected 39 million men, women and children in the U.S. and 1 billion worldwide in 2019.
Amitriptyline Market Report Coverage
||Market Size in 2020:
||US$ 527.4 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 762.2 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of the Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Strength: 10 mg tablets, 25 mg tablets, 50mg tablets, 75 mg tablets, 100 mg tablets, 150 mg tablets.
- By Indication: Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, Others.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.
- Strong product pipeline
- Increasing prevalence of neuropathic pain and migraine
|Restraints & Challenges:
- Side effects associated with amitriptyline
Global Amitriptyline Market: Restraint
Intolerable side effects of amitriptyline are expected to affect demand for the drug. The side effects of amitriptyline include nausea, vomiting, drowsiness, weakness or tiredness, nightmares, headaches, dry mouth, constipation, changes in sex drive and others. Thus, side effects associated with the drug can shift patient’s preference to alternative treatments. Such factors are expected to hamper the growth of the market.
Figure 2. Global Amitriptyline Market Value (US$ Mn), by Region, 2020
The North America amitriptyline market is expected to exhibit significant growth during the forecast period owing to the increasing prevalence of neuropathic pain among the U.S. population. According to a study published in the Journal of Pain Research, in 2018, the reported prevalence of neuropathic pain in the U.S. was 10%. The National Institute of Neurological Disorders and Stroke (NINDS) reported that 20 million Americans have some type of peripheral neuropathy.
Major players operating in the global amitriptyline market are Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.